In an article featured in Prelude Therapeutics investor news, Prelude Therapeutics announced the pricing of a $90 million underwritten offering to support the continued advancement of its precision oncology pipeline. The financing includes shares of voting common stock and pre-funded warrants, with gross proceeds expected to strengthen the company’s operational runway and support research, clinical development, and broader corporate initiatives.

The offering was led by new investor RA Capital Management, with participation from additional healthcare-focused investors. According to the company, the funding will primarily be used to accelerate development across its portfolio of innovative cancer therapies and expand resources for future growth.

This milestone reflects continued confidence in Prelude’s scientific strategy and underscores the momentum of companies advancing breakthrough therapies within the life sciences sector.

Read the full article: https://investors.preludetx.com/news-releases/news-release-details/prelude-therapeutics-announces-pricing-900-million-underwritten

Source: Prelude Therapeutics Investor Relations, April 2026